In Brain News, Research News

Coronavirus update for people with a brain tumour: treatment, vaccinations, shielding

‘People should continue to shield after they have been vaccinated: we do not know whether vaccination can prevent transmission.” Professor Peter Johnson, National Clinical Director for Cancer at NHS England

Yesterday we had the NHS updates for the current situation in England; we’re really lucky to have the ear of Cally Palmer and her team. Cally is the NHS England’s National Cancer Director. These meetings are a valuable source of information, although it does feel a little Ground Hog Day. It is – but it is different from April 2020.

What is the current state of play?

Most importantly – the NHS is open for cancer patients. This means that if you have an appointment you should plan on attending it. Hospitals are well prepared for managing if we are attending face to face appointments. If anything, this is not new ground for them – they have been working in this space for nearly a year now.

As ever, it is not one size fits all. Bottom line? There isn’t significant disruption for people living with cancer. A few hospitals are severely impacted by this new COVID variant. These hospitals are in London and the east. Others are busy but managing, and some are not impacted at all. It would be misguided of us to give a blanket overview, so contact your support specialist – they understand the picture on the ground. The other message we’d add is do not be seduced by what you hear on the media; it isn’t all negative; most cancer services are being delivered as normal.

Shielding

We’ve broken down the government’s latest advice to patients that are clinically extremely vulnerable. Read it here.

Surgery

Surgery is being prioritised in hospitals that are struggling. Phase 1 saw the creation of the cancer surgical hubs – these are being reinstated. The purpose of the surgical hubs is to ensure the continuity of urgent and essential cancer surgery. These hubs are COVID safe.

Patients are being prioritised to make sure that those who need surgery have it. Those that need immediate life-saving intervention and those who need urgent surgery will be top of the list. Any patients whose surgery can be safely delayed MAY find that their surgery is delayed, but if this happens to you then you should be given a new date. Some of this rescheduling is unavoidable. If you are struggling with the uncertainty around this then please speak with us. We can help.

Radiotherapy and chemotherapy

Radiotherapy and chemotherapy treatments are being delivered and are unaffected – this is because they are delivered by a specialised workforce that isn’t being redeployed to COVID patients.

Vaccination

If you are invited to have the vaccine, you should have it; the timing is not critical. It is a case of risk v benefit, so it is more important that you are vaccinated and people with brain tumours have as good as a response as people who don’t have cancer. The case is different with people who are living with blood cancers, such as leukaemia. These people may have a slightly reduced immune response.

We answered your questions about the COVID vaccine here. 

Diagnostics

A word on diagnostics. Screening for cancer is continuing and there are no reports of delays with diagnostic pathways. But we know that diagnosing a brain tumour is complicated. If you have any concerns contact your GP or talk with us. You may find this information useful.

 

 

 

collage scaled
Nicci, Tom and Noah’s storyCampaign News, Fundraising News, little brainstrust
south central whos who cns
Who’s Who? The Neuro-oncology CNSBrain News

Introduction

The Brain Tumour Data Dashboard lets you explore up -to-date, population level data about the brain tumours diagnosed in England between 2013 and 2015. Using the drop down menus on the left you can select different groups of patients to view in the charts below. In these charts the number of patients for every 100 diagnoses is displayed as images of people. Patients have been grouped by date of diagnosis, type of tumour, age, gender, and region in England.

For each group of patients you can explore the different routes to diagnosis, the proportion of those who received chemotherapy or radiotherapy, as well as the survival of the patients within each group. For more information about what these metrics mean please see the glossary.

How to use

  1. Select the year of diagnosis using the drop down menu.
  2. Select your patient group of interest from the four drop down menus in the following order:
    1. Tumour group
    2. Age at diagnosis
    3. Region of England
    4. Gender of patient
  3. To view a second chart to compare different groups of patients, click the ‘compare’ button.The second chart will appear below the first chart.

*Note that the tool is best used on a laptop or tablet rather than a mobile phone*

Unavailable data

Some of the data in these charts is not available.There are two main reasons for this:

  1. How the data has been grouped

If you cannot select a patient group from the drop down menus, the data is unavailable because of how the data has been organised.

Public Health England has grouped the data like a branching tree. The bottom of the tree contains all the patients with brain tumours, and then each branch divides the data by a certain characteristics, like age, or location of tumour. But the data is divided in an order, starting with location of the tumour (endocrine or brain), then by age, region, and gender. Age is at the start because it makes a bigger difference to survival rates and treatment rates than gender or region. Sometimes, after the data has been split by type of tumour and age, there is not enough data to be split again. This is because to protect patient confidentiality groups cannot contain less than 100 patients. Because some groups cannot be split further, you cannot create ‘totals’ for everyone by region or gender. For example, you cannot see results for all ages by region, or all brain tumours by gender. If these totals were calculated and released, it might be possible to identify patients, which is why Public Health England cannot release this data.

  1. Statistical reasons and data availability

If you can select a patient group from the chart menus, but the chart does not display, the data is unavailable for one of several reasons:

  1. Data is not yet available for the selected year from Public Health England.
  2. Data is not available because the data quality is too poor to release this statistic.
  3. Data is not available as the statistic is not appropriate for this group.
  4. Data is not available because the standard error of the estimate was greater than 20% and so the estimate has been supressed.

Up to date brain tumour data

Brain tumour data may influence the decisions you make about your care. Data also helps you understand the bigger picture, or landscape, in which you find yourself.

Brain tumour data and statistics influence the focus, and work of organisations like brainstrust. The information helps us to understand the scale and impact of the problems we are setting out to solve.

This tool helps you understand the landscape in which you find yourself having been diagnosed with a brain tumour. This landscape can be particularly tricky to navigate as there are many different types of brain tumour, all of which have a different impact.

The information you see represents the most up-to-date, official, population level brain tumour data available for England. Over time we will be adding to the brain tumour data available and publishing reports, with recommendations, as a result of what we learn from this data.

The data behind this content has come from Public Health England’s National Cancer Registration and Analysis Service (NCRAS) and is a direct result of the ‘Get Data Out’ project.

This project provides anonymised population level brain tumour data for public use in the form of standard output tables, accessible here: http://cancerdata.nhs.uk/standardoutput

Incidence

The number or rate (per head of population) of new cases of a disease diagnosed in a given population during a specified time period (usually a calendar year). The crude rate is the total number of cases divided by the mid-year population, usually expressed per 100,000 population.

Malignant

Malignant tumours which grow by invasion into surrounding tissues and have the ability to metastasise to distant sites

Mortality

The number or rate (per head of population) of deaths in a given population during a specified time period (usually a calendar year). The crude rate is the total number of deaths divided by the mid-year population, usually expressed per 100,000 population.

Non-malignant

Not cancerous. Non-malignant tumours may grow larger but do not spread to other parts of the body.

Survival

The length of time from the date of diagnosis for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the survival is one way to see how well a new treatment works. Also called ‘overall survival’ or ‘OS’.

Routes to Diagnosis

Under the ‘Routes to Diagnosis’ tab in the Brain Tumour Data Dashboard, you can explore the ways patients have been diagnosed with brain tumours. There are many ways, or routes, for cancers to be diagnosed in the NHS. A ‘route to diagnosis’ is the series of events between a patient and the healthcare system that leads to a diagnosis of cancer. The routes include:

  1. Two Week Wait

Patients are urgently referred by their GP for suspected cancer via the Two Week Wait system and are seen by a specialist within 2 weeks where they are diagnosed.

  1. GP referral

Diagnosis via a GP referral includes routine and urgent referrals where the patient was not referred under the Two Week Wait system.

  1. Emergency Presentation

Cancers can be diagnosed via emergency situations such as via A&E, emergency GP referral, emergency transfer or emergency admission.

  1. Outpatient

Outpatient cancer diagnoses include diagnoses via an elective route which started with an outpatient appointment that is either a self-referral or consultant to consultant referral. (It does not include those under the Two Week Wait referral system).

  1. Inpatient elective

Diagnosis via an inpatient elective route is where diagnosis occurs after the patient has been admitted into secondary care from a waiting list, or where the admission is booked or planned.

  1. Death Certificate Only

Diagnoses made by Death Certificate Only are made where there is no more information about the cancer diagnosis other than the cancer related death notifications. The date of diagnosis is the same as that of the date of death.

  1. Unknown

For some patients with a cancer diagnosis, there is no relevant data available to understand the route to diagnosis.

 

More information

If any of the statistical terms in this section of the brainstrust website are hard to understand, we recommend looking them up here:

Cancer Research UK’s Cancer Statistics Explained

http://www.cancerresearchuk.org/health-professional/cancer-statistics/cancer-stats-explained/statistics-terminology-explained#heading-Seven

If you are looking for help understanding terms relating specifically to brain tumours, and treatment, then the brainstrust glossary is available here:

https://www.brainstrust.org.uk/advice-glossary.php